260 related articles for article (PubMed ID: 18645097)
1. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
Yang GC; Chiu RJ; Gillman GS
Arch Facial Plast Surg; 2008; 10(4):273-9. PubMed ID: 18645097
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids.
Hui JI; Lee WW
Ophthalmic Plast Reconstr Surg; 2007; 23(6):433-8. PubMed ID: 18030112
[TBL] [Abstract][Full Text] [Related]
3. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study.
Gassner HG; Sherris DA
Mayo Clin Proc; 2000 Jul; 75(7):701-4. PubMed ID: 10907385
[TBL] [Abstract][Full Text] [Related]
4. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines.
Lizarralde M; Gutiérrez SH; Venegas A
Dermatol Surg; 2007 Nov; 33(11):1328-33; discussion 1333. PubMed ID: 17958584
[TBL] [Abstract][Full Text] [Related]
6. Botox: shaken, not stirred.
Kazim NA; Black EH
Ophthalmic Plast Reconstr Surg; 2008; 24(1):10-2. PubMed ID: 18209633
[TBL] [Abstract][Full Text] [Related]
7. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
9. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
[TBL] [Abstract][Full Text] [Related]
10. A pilot study on the effect of epinephrine on botulinum toxin treatment for periorbital rhytides.
Hantash BM; Gladstone HB
Dermatol Surg; 2007 Apr; 33(4):461-8. PubMed ID: 17430381
[TBL] [Abstract][Full Text] [Related]
11. A double-blinded, placebo-controlled study of Botox for the treatment of subjects with chin rhytids.
Beer K; Yohn M; Closter J
J Drugs Dermatol; 2005; 4(4):417-22. PubMed ID: 16004014
[TBL] [Abstract][Full Text] [Related]
12. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
Vadoud-Seyedi J; Simonart T
Br J Dermatol; 2007 May; 156(5):986-9. PubMed ID: 17286630
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments.
Niamtu J
J Oral Maxillofac Surg; 2003 Mar; 61(3):317-24. PubMed ID: 12618971
[TBL] [Abstract][Full Text] [Related]
14. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2003 May; 29(5):461-7. PubMed ID: 12752512
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous vs intramuscular botulinum toxin: split-face randomized study.
Gordin EA; Luginbuhl AL; Ortlip T; Heffelfinger RN; Krein H
JAMA Facial Plast Surg; 2014; 16(3):193-8. PubMed ID: 24699554
[TBL] [Abstract][Full Text] [Related]
16. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use.
Sloop RR; Cole BA; Escutin RO
Neurology; 1997 Jan; 48(1):249-53. PubMed ID: 9008526
[TBL] [Abstract][Full Text] [Related]
17. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard.
Nestor MS; Ablon GR
J Drugs Dermatol; 2011 Oct; 10(10):1148-57. PubMed ID: 21968665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit.
Jabor MA; Kaushik R; Shayani P; Ruiz-Razura A; Smith BK; Morimoto KW; Cohen BE
Plast Reconstr Surg; 2003 Jun; 111(7):2419-26; discussion 2427-31. PubMed ID: 12794491
[TBL] [Abstract][Full Text] [Related]
19. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection.
Hexsel D; Rutowitsch MS; de Castro LC; do Prado DZ; Lima MM
Dermatol Surg; 2009 Jun; 35(6):933-9; discussion 940. PubMed ID: 19397645
[TBL] [Abstract][Full Text] [Related]
20. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial.
Alam M; Dover JS; Arndt KA
Arch Dermatol; 2002 Apr; 138(4):510-4. PubMed ID: 11939813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
